For the quarter ending 2025-09-30, ARCT had -$16,107K decrease in cash & cash equivalents over the period. -$17,332K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 17,152 | - |
| Total research and development | 87,736 | - |
| General and administrative | 10,398 | - |
| Other | -3,063 | - |
| Net loss | -13,448 | -23,256 |
| Depreciation and amortization | 763 | 1,580 |
| Share-based compensation expense | 5,729 | 12,862 |
| Foreign currency transaction loss | -170 | -149 |
| Accounts receivable | -9,253 | 13,230 |
| Prepaid expense and other assets | 57 | -4,145 |
| Right-of-use assets | -955 | -1,880 |
| Accounts payable | -5,045 | 3,429 |
| Accrued liabilities | -5,417 | -14,301 |
| Deferred revenue | -8,986 | -12,086 |
| Lease liabilities | -1,068 | -2,065 |
| Net cash used in operating activities | -17,151 | -40,893 |
| Acquisition of property and equipment | 181 | 137 |
| Net cash used in investing activities | -181 | -137 |
| Proceeds from exercise of stock options | 640 | 469 |
| Proceeds from the issuance of common stock under equity plans | 585 | - |
| Proceeds from debt | 0 | 15,000 |
| Payments on debt obligations | 0 | 15,000 |
| Net cash provided by financing activities | 1,225 | 469 |
| Net decrease in cash, cash equivalents and restricted cash | -16,107 | -40,561 |
| Cash and cash equivalents at beginning of period | 293,913 | - |
| Cash and cash equivalents at end of period | 237,245 | - |
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)